Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS
Proprietary TRACER™ capsid
According to Benzinga Pro data, during Q3, Voyager Therapeutics (NASDAQ:VYGR) posted sales of $1.50 million. Earnings were up 12.03%, but Voyager Therapeutics still reported an overall loss of $25.15 million.
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.67) per share. This is a 129.52 percent decrease over earnings of $2.27 per share from the same period last year. The company reported $1.50 million in
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock increased by 28.63% to $5.66 during Monday's after-market session. The market value of their outstanding shares is at $47.1 million.